During the recent session, Akebia Therapeutics Inc (NASDAQ:AKBA)’s traded shares were 0.9 million, with the beta value of the company hitting 0.82. At the last check today, the stock’s price was $3.04, reflecting an intraday gain of 5.56% or $0.16. The 52-week high for the AKBA share is $2.97, that puts it up 2.3 from that peak though still a striking 73.68% gain since the share price plummeted to a 52-week low of $0.80. The company’s market capitalization is $798.41M, and the average trade volume was 4.82 million shares over the past three months.
Akebia Therapeutics Inc (AKBA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AKBA has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.04.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Akebia Therapeutics Inc (AKBA) registered a 5.56% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.56% in intraday trading to $3.04, hitting a weekly high. The stock’s 5-day price performance is 8.19%, and it has moved by 25.10% in 30 days. Based on these gigs, the overall price performance for the year is 176.36%.
The consensus price target of analysts on Wall Street is $6.5, which implies an increase of 53.23% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $7 respectively. As a result, AKBA is trading at a discount of -130.26% off the target high and -97.37% off the low.
Akebia Therapeutics Inc (AKBA) estimates and forecasts
In the rating firms’ projections, revenue will increase 23.99% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 47.3M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 44.67M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 43.65M and 37.43M respectively. In this case, analysts expect current quarter sales to grow by 8.38% and then jump by 19.35% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 32.58%. While earnings are projected to return 68.48% in 2025.
AKBA Dividends
Akebia Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
The next largest institutional holding, with 9.28 million shares, is of VANGUARD GROUP INC’s that is approximately 4.4235% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.46 million.
Also, the Mutual Funds coming in first place with the largest holdings of Akebia Therapeutics Inc (AKBA) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 7.84 shares. This amounts to just over 2.99 percent of the company’s overall shares, with a $24.23 million market value. The same data shows that the other fund manager holds slightly less at 5.84, or about 2.23% of the stock, which is worth about $18.06 million.
